SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
This Quarter Return
+2.37%
1 Year Return
+0.55%
3 Year Return
-0.75%
5 Year Return
–
10 Year Return
–
AUM
$406M
AUM Growth
+$406M
(+2.9%)
Cap. Flow
+$5.93M
Cap. Flow
% of AUM
1.46%
Top 10 Holdings %
Top 10 Hldgs %
76.7%
Holding
35
New
7
Increased
8
Reduced
8
Closed
12
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$34.5M |
| 2 |
Eli Lilly
LLY
|
$34.2M |
| 3 |
Viatris
VTRS
|
$26.8M |
| 4 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$20.6M |
| 5 |
CVS Health
CVS
|
$18.2M |
Top Sells
| 1 |
Sanofi
SNY
|
$69.6M |
| 2 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$18.7M |
| 3 |
MiMedx Group
MDXG
|
$16.1M |
| 4 |
Globus Medical
GMED
|
$13.2M |
| 5 |
Myriad Genetics
MYGN
|
$9.96M |
Sector Composition
| 1 | Healthcare | 90.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Halozyme
HALO
$8.56B
| $52.4M | 12.9% | 4,087,264 +597,400 | +17% | +$7.66M |
|
|
ESRX
2
DELISTED
Express Scripts Holding Company
ESRX
| $40.9M | 10.08% | 641,301 +118,000 | +23% | +$7.53M |
|
|
3
Viatris
VTRS
$12.3B
| $35.2M | 8.67% | 907,100 +690,400 | +319% | +$26.8M |
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $34.5M | 8.49% | +749,200 | New | +$34.5M |
|
|
5
Eli Lilly
LLY
$657B
| $34.2M | 8.41% | +415,200 | New | +$34.2M |
|
6
Elevance Health
ELV
$71.8B
| $27.2M | 6.69% | 144,350 -26,100 | -15% | -$4.91M |
|
7
Gilead Sciences
GILD
$140B
| $26.5M | 6.51% | 373,800 +53,200 | +17% | +$3.77M |
|
8
Abbott
ABT
$231B
| $21.9M | 5.39% | 450,700 +63,900 | +17% | +$3.11M |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $20.6M | 5.06% | +391,400 | New | +$20.6M |
|
|
10
CVS Health
CVS
$92.8B
| $18.2M | 4.49% | +226,600 | New | +$18.2M |
|
11
DaVita
DVA
$9.85B
| $16.8M | 4.13% | +258,800 | New | +$16.8M |
|
|
FWP
12
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $13.3M | 3.27% | 652,500 +180,200 | +38% | +$3.66M |
|
|
NDRM
13
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $10.7M | 2.63% | 357,400 +33,700 | +10% | +$1.01M |
|
14
TG Therapeutics
TGTX
$4.65B
| $9.74M | 2.4% | 969,300 -170,600 | -15% | -$1.71M |
|
|
LPNT
15
DELISTED
LifePoint Health, Inc.
LPNT
| $8.98M | 2.21% | 133,700 -9,700 | -7% | -$651K |
|
|
ALDR
16
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $6.39M | 1.57% | 557,770 +342,700 | +159% | +$3.92M |
|
|
CORI
17
DELISTED
Corium International, Inc.
CORI
| $6M | 1.48% | 803,766 -704,500 | -47% | -$5.26M |
|
|
CNCE
18
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $5.75M | 1.42% | 412,145 -4,700 | -1% | -$65.6K |
|
|
ACHN
19
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $4.97M | 1.22% | +1,082,100 | New | +$4.97M |
|
20
Travere Therapeutics
TVTX
$1.56B
| $4.78M | 1.18% | 246,289 -183,900 | -43% | -$3.57M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $3.09M | 0.76% | +273,500 | New | +$3.09M |
|
|
FOMX
22
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.64M | 0.65% | 569,197 -5,600 | -1% | -$26K |
|
23
Rocket Pharmaceuticals
RCKT
$354M
| $1.6M | 0.39% | 843,722 -8,300 | -1% | -$15.8K |
|
|
BIVV
24
DELISTED
Bioverativ Inc. Common Stock
BIVV
| – | – | -343,800 | Closed | -$18.7M |
|
|
25
Globus Medical
GMED
$8.27B
| – | – | -447,100 | Closed | -$13.2M |
|